Latest Manufacturing News

Arafura Rare Earths has taken a decisive step forward on its Nolans Project, announcing a Final Investment Decision and securing over A$700 million in cash and term deposits as it prepares to start construction in September 2026.

SRJ Technologies has transitioned from contract awards to operational delivery in the Middle East, supported by a recent A$2.57 million capital raise and a strategic partnership with robotics OEM Nexxis.

Skin Elements has secured an exclusive New Zealand distribution agreement for its ECO-Nurture bio-stimulant, raised $1.47 million through options and placement, and refreshed its board after shareholder votes.

Structural Monitoring Systems Plc (ASX: SMN) reported a milestone FY26 with record revenue of $32.5 million and net profit rising to $1.2 million, driven by strong avionics growth and progressing FAA certification for its CVMTM smart sensor technology.

Canadian Phosphate Limited has completed its acquisition of the Diamond Mountain Phosphate Project in Utah, adding a significant 49.9 million tonne phosphate resource to its portfolio. The company plans extensive exploration to validate and upgrade the resource to JORC standards, positioning itself for growth in North American fertiliser and battery markets.

Finder Energy has secured key regulatory approval for its KTJ Project in Timor-Leste and raised $27 million to advance development, positioning for a Final Investment Decision in Q3 2026.

Zelira Therapeutics has raised nearly US$33 million into its HOPE® 1 special purpose vehicle, valuing the SPV at about US$66 million post-money. The funds will advance FDA regulatory submissions and Phase 1 clinical trials for its autism-targeting cannabinoid drug.

Livium Ltd has locked in A$1.575 million in initial funding from The Lind Partners, with potential to raise up to A$11.75 million over two years, while offering shareholders a discounted share purchase plan to support its recycling growth strategy.

Actinogen Medical’s pivotal XanaMIA Alzheimer’s trial stays on track for November topline results, buoyed by strong open-label extension enrolment and aligned EMA-FDA regulatory advice. A new antidepressant study publication and fresh patents add momentum, supported by a $16.7 million cash runway to mid-2027.

Alterity Therapeutics has cleared a major regulatory hurdle with the FDA endorsing a single pivotal Phase 3 trial for its ATH434 drug in Multiple System Atrophy, setting the stage for trial initiation by the end of 2026.

Island Pharmaceuticals has marked a major step forward in its antiviral program with the start of GMP manufacturing for Galidesivir, expanded USAMRIID collaboration, and FDA orphan drug designation. Regulatory approvals for compassionate use in Uganda’s Ebola outbreak and a new dose optimisation study with Texas Biomed further de-risk the pathway to approval.

EBR Systems advanced its wireless cardiac pacing rollout in Q2 2026, completing 46 implants and signing 17 new purchasing contracts while shifting focus to deeper utilisation within existing accounts.